To address shortage, Novo Nordisk will cut production of Victoza to boost supply of Ozempic

发布时间： 2023-11-30 阅读：115次

分享

Recently, according to Fierce Pharma, unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza to make more Ozempic.

Novo and the European Medicines Agency (EMA) divulged the move in a letter to healthcare professionals, warning of a growing shortage of both medicines that is set to intensify during the rest of the fourth quarter.

It is stated in the letter that, for Ozempic, intermittent shortages are expected throughout 2024. For Victoza, shortages are expected at least until Q2 2024. The supply shortage is not related to a quality defect of the products or a safety issue. Novo Nordisk will limit the supply of the starting dose for Ozempic (0.25 mg), which is expected to limit the initiation of new patients, to mitigate the increasing demand on the maintenance doses (Ozempic 0.5 mg and 1 mg). It is recommended to limit initiations of new patients during the shortage and until the supply situation improves which is expected in Q1 2024.